



Uloric[®] (febuxostat) – First-time generic

- On July 1, 2019, [Alembic](#) and [Mylan](#) launched AB-rated generic versions of Takeda's [Uloric \(febuxostat\)](#) tablets.
 - In addition, Sun Pharmaceuticals received FDA approval of an [AB-rated](#) generic version of Uloric. Launch plans for this generic are pending.
- Uloric is approved for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of [allopurinol](#), who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
- Uloric carries a boxed warning for cardiovascular death.
- According to IQVIA[™], Uloric had estimated U.S. sales of \$578 million for twelve months ending December 2018.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.